Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics
Lexicon Pharmaceuticals, Inc. (LXRX)
Today's Latest Price: $1.38 USD
Updated Oct 20 4:00pm
Add LXRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
LXRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LXRX is -29.97 -- better than just 0.56% of US stocks.
- With a price/earnings ratio of 3.87, Lexicon Pharmaceuticals Inc P/E ratio is greater than that of about merely 3.6% of stocks in our set with positive earnings.
- Revenue growth over the past 12 months for Lexicon Pharmaceuticals Inc comes in at 642.43%, a number that bests 98.76% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Lexicon Pharmaceuticals Inc are CTXS, HPQ, IRWD, GDDY, and KODK.
- LXRX's SEC filings can be seen here. And to visit Lexicon Pharmaceuticals Inc's official web site, go to www.lexpharma.com.
LXRX Stock Price Chart Interactive Chart >
LXRX Price/Volume Stats
| Current price | $1.38 | 52-week high | $5.33 |
| Prev. close | $1.42 | 52-week low | $1.37 |
| Day low | $1.37 | Volume | 1,028,400 |
| Day high | $1.43 | Avg. volume | 1,176,905 |
| 50-day MA | $1.61 | Dividend yield | N/A |
| 200-day MA | $2.15 | Market Cap | 147.81M |
Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.
LXRX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $1.38 | $4.05 | 185% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Lexicon Pharmaceuticals Inc. To summarize, we found that Lexicon Pharmaceuticals Inc ranked in the 69th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 186.83% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Lexicon Pharmaceuticals Inc, consider:
- 38% of the company's capital comes from equity, which is greater than only 18.1% of stocks in our cash flow based forecasting set.
- Lexicon Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 15.51% of tickers in our DCF set.
- As a business, Lexicon Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 180% |
| 1% | 183% |
| 2% | 185% |
| 3% | 188% |
| 4% | 191% |
| 5% | 194% |
Want more companies with a valuation profile/forecast similar to that of Lexicon Pharmaceuticals Inc? See ALXN, SGRY, FTLF, GTS, and PDEX.
Loading social stream, please wait...